Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.
作者信息
Lytvyn Y, Georgakopoulos J R, Mufti A, Devani A R, Gooderham M J, Jain V, Lansang P, Vender R, Prajapati V H, Yeung J
机构信息
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
出版信息
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e94-e95. doi: 10.1111/jdv.17749. Epub 2021 Oct 28.
Abstract
摘要
相似文献
1
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.使用阿普斯特治疗的银屑病患者中新冠病毒疾病的发病率和预后：一项多中心回顾性队列研究
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e94-e95. doi: 10.1111/jdv.17749. Epub 2021 Oct 28.
2
SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.接受生物疗法或阿普米拉斯治疗的银屑病患者的新型冠状病毒2型血清学研究：意大利疫情重灾区93例患者的研究
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e86-e88. doi: 10.1111/jdv.17721. Epub 2021 Oct 14.
3
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.银屑病患者的机会性病毒感染：在新冠疫情时代阿普米拉斯更安全的选择。
Dermatol Ther. 2020 Jul;33(4):e13618. doi: 10.1111/dth.13618. Epub 2020 Jun 4.
4
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.在加拿大两家学术医院诊所和一家社区诊所的COVID-19大流行期间，患者驱动的阿普斯特停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
5
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.阿普米司特治疗 COVID-19 大流行期间成人银屑病的临床疗效、改善速度和安全性。
Dermatol Ther. 2020 Jul;33(4):e13722. doi: 10.1111/dth.13722. Epub 2020 Jun 24.
6
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
7
A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.临床实践中阿普米拉斯单药治疗与联合治疗斑块状银屑病的比较：一项加拿大多中心回顾性研究。
J Am Acad Dermatol. 2018 Mar;78(3):623-626. doi: 10.1016/j.jaad.2017.09.060. Epub 2017 Oct 6.
8
Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.与阿普米司特单药治疗相比，阿普米司特联合治疗1年后斑块状银屑病治疗反应的维持情况：一项多中心回顾性研究。
J Am Acad Dermatol. 2018 Nov;79(5):953-956. doi: 10.1016/j.jaad.2018.04.043. Epub 2018 May 4.
9
Drug survival of apremilast in patients treated for psoriasis in a real-world setting.在真实临床环境中接受治疗的银屑病患者中阿普米司特的药物留存率
J Am Acad Dermatol. 2018 Oct;79(4):760-761. doi: 10.1016/j.jaad.2018.03.028. Epub 2018 Mar 26.
10
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study.银屑病患者感染新型冠状病毒肺炎的风险：一项回顾性队列研究。
J Am Acad Dermatol. 2022 Dec;87(6):1395-1398. doi: 10.1016/j.jaad.2022.07.040. Epub 2022 Sep 20.
引用本文的文献
1
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.银屑病、银屑病关节炎和中轴型脊柱关节炎患者 COVID-19 结局不良的相关特征：COVID-19 PsoProtect 和全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14.
2
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
3
Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?炎症导致 COVID-19 恶化：皮肤炎症呢？
Int J Mol Sci. 2022 Oct 14;23(20):12260. doi: 10.3390/ijms232012260.
4
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.2019年冠状病毒病大流行期间中重度银屑病的治疗：经验教训与机遇
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
5
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis.阿普司特可改善银屑病患者的内皮糖萼完整性、血管及左心室心肌功能。
Pharmaceuticals (Basel). 2022 Jan 30;15(2):172. doi: 10.3390/ph15020172.
本文引用的文献
1
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.COVID-19 大流行期间生物治疗的银屑病患者监测：单中心经验。
Dermatol Ther. 2021 Jan;34(1):e14700. doi: 10.1111/dth.14700. Epub 2020 Dec 28.
2
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.生物制剂治疗的银屑病患者中 SARS-CoV-2 感染的流行率和 COVID-19 病程的严重程度。
J Dermatolog Treat. 2022 May;33(3):1581-1584. doi: 10.1080/09546634.2020.1861177. Epub 2020 Dec 22.
3
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.意大利 COVID-19 大流行期间接受生物制剂治疗的慢性斑块型银屑病患者的特征：来自 PSO-BIO-COVID 观察性研究的风险分析。
Expert Opin Biol Ther. 2021 Feb;21(2):271-277. doi: 10.1080/14712598.2021.1853698. Epub 2021 Jan 13.
4
Future perspective: biologic agents in patients with severe COVID-19.未来展望：重症 COVID-19 患者的生物制剂
Immunopharmacol Immunotoxicol. 2021 Feb;43(1):1-7. doi: 10.1080/08923973.2020.1818770. Epub 2020 Sep 14.
5
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.西班牙北部接受生物免疫抑制剂治疗的 COVID-19 合并银屑病和银屑病关节炎患者与接受阿普米司特治疗患者的比较。
Dermatol Ther. 2020 Nov;33(6):e13961. doi: 10.1111/dth.13961. Epub 2020 Jul 27.
6
COVID-19 and psoriasis: biologic treatment and challenges.COVID-19 与银屑病：生物治疗及挑战
J Dermatolog Treat. 2022 Mar;33(2):699-703. doi: 10.1080/09546634.2020.1789051. Epub 2020 Jul 6.
7
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.银屑病患者接受全身治疗或生物治疗不会增加患重症 COVID-19 的风险。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679. doi: 10.1111/jdv.16761. Epub 2020 Jul 9.
8
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.阿普司特作为治疗新冠肺炎的潜在选择：一名银屑病患者无感染症状。
Dermatol Ther. 2020 Jul;33(4):e13668. doi: 10.1111/dth.13668. Epub 2020 Jun 24.
9
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.在加拿大两家学术医院诊所和一家社区诊所的COVID-19大流行期间，患者驱动的阿普斯特停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
10
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).银屑病患者阿普米司特的长期安全性和耐受性：来自 2 项 3 期、随机、对照试验（ESTEEM1 和 2）≥156 周的汇总安全性分析。
J Am Acad Dermatol. 2017 Aug;77(2):310-317.e1. doi: 10.1016/j.jaad.2017.01.052. Epub 2017 Apr 14.
Zotero 插件